Berlin, Germany, December 21, 2013 --(PR.com
)-- Over the past 20 years, the Berlin-based contract research organization, ICRC-Weyer, has seen constant and steady growth. However, perhaps just a few of those years have shaped the face of the company the same way as 2013 has.
Prof Dr Geerd Weyer, who founded the company in 1993, looks back at the long list of achievements by the ICRC-Weyer team over the past 12 months. "2013 marked the 20th anniversary of the company and it was truly an exciting year for us," says Prof Weyer. "We became a CDISC Gold Member in March and only a few months later, we introduced a revolutionary program to drastically facilitate the CDISC mapping process for SDTM and ADaM data sets. The program was first introduced at the Pharmaceutical User Software Exchange (PhUSE) in Brussels in October. In the area of drug safety, we boosted our services portfolio for SAE reporting in Investigator-Initiated Trials and extended our Pharmacovigilance Writing services and our Pharmacovigilance Risk Management." According to Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer, it is by integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments.
ICRC-Weyer launched a new website this year in order to provide clients with a more comprehensive and tailored overview of the company’s clinical research services for each distinct type of trials: Medicinal Products, Medical Devices, Advanced Therapies and Nutraceuticals. The CRO has developed special expertise in all of these areas with the delivery of not just high-quality functional services for large pharmaceutical, biotech and medical device clients but also complete turnkey solutions for small to mid-sized companies. Thus, ICRC-Weyer is able to handle complete trial projects, from study design and protocol development to the statistical analysis and writing of the final clinical study report.
A further highlight of 2013 was the formation of the MEDIS Research Group, a strategic partnership between ICRC-Weyer and Allied Clinical Management, a study management and monitoring CRO also based in Berlin. "The formation of the MEDIS Research Group was a move to better meet requirements of clinical trial sponsors through consolidation and specialization," Prof Weyer continues. "This partnership will enable us to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process."
ICRC-Weyer participated in a number of industry events in 2013. The company was present at conferences such as Partnerships in Clinical Trials (PCT), Pharmaceutical User Software Exchange (PhUSE), Global Innovation in Clinical Research & Outsourcing (GICRO) as well as numerous seminars and workshops, e.g. the EFGCP workshop on risk-based monitoring and a number of regional pharmaceutical and biotechnology events. "This presence enabled us to meet with existing clients and partners, both regional and international, as well as to discuss clinical trial outsourcing requirements with potential partners," says Prof Weyer.
The company founder concludes: "It was the joint efforts of the entire team at ICRC-Weyer which made this year a tremendous success and helped shape the face of the company to prepare us for the long road ahead into the next 20 years in business."
ICRC-Weyer is an established all-phase contract research organization (CRO) based in Berlin, Germany. The company provides both functional services and complete turnkey solutions for all stages of the clinical development process, including data management, biostatistics, medical writing and monitoring services.
In addition to delivering clinical research services for medicinal products, ICRC-Weyer has developed special expertise in Medical Devices, Advanced Therapies and Nutrition.